VBK Stock Analysis: VERBIO Vereinigte BioEnergie | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 1.710m EUR | 12M Return: 118.8% | DE000A0JL9W6 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.63M
Qual. Beats: 0
Rev. Trend: -2.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Verbio SE is a German renewable fuels and bio-based chemicals producer headquartered in Leipzig, operating across Germany, Europe, and North America. The company runs three segments-Biodiesel, Bioethanol/Biomethane, and Other-manufacturing biodiesel, biomethane, bioethanol, pharma-glycerine, olefin metathesis catalysts, and bio-based chemicals, alongside downstream products such as animal feeds (Proti Flow, Grain Pro), Sterocellent phytosterols, and fertilizers. It also provides trading, transport, and logistics services, serving end-markets that include cosmetics, food, pharmaceuticals, fuels, renewable chemicals, fragrances, plastics, agrochemicals, and agriculture, with customers spanning oil companies, energy utilities, farmers, fleet operators, and LNG/CNG filling stations. The company was founded in 2006 and was renamed from VERBIO Vereinigte BioEnergie AG to Verbio SE in December 2023.
Within the GICS Materials sector under Specialty Chemicals, Verbio sits at the intersection of renewable fuels and bio-based industrial inputs, converting agricultural feedstocks (such as rapeseed and grain) into fuel substitutes and chemical intermediates. Its integrated model-spanning production, trading, and logistics-allows it to capture value across the renewable energy and bioeconomy value chain, while its biomethane and biodiesel offerings position it in markets driven by decarbonization mandates and biofuel blending obligations.
- Biodiesel margins track rapeseed feedstock costs and heating oil spreads
- Biomethane demand accelerates on EU RED III renewable targets
- North American capacity expansion diversifies segment revenue mix
| Net Income: 64.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 14.95 > 1.0 |
| NWC/Revenue: 13.32% < 20% (prev 15.71%; Δ -2.39% < -1%) |
| CFO/TA 0.12 > 3% & CFO 164.6m > Net Income 64.0m |
| Net Debt (163.1m) to EBITDA (169.0m): 0.97 < 3 |
| Current Ratio: 1.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.6m) vs 12m ago 2.93% < -2% |
| Gross Margin: 15.92% > 18% (prev 6.49%; Δ 9.43% > 0.5%) |
| Asset Turnover: 141.2% > 50% (prev 123.1%; Δ 18.11% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.18 (Total Current Assets 608.2m - Total Current Liabilities 358.7m) / Total Assets 1.37b |
| B: 0.19 (Retained Earnings 261.6m / Total Assets 1.37b) |
| C: 0.09 (EBIT TTM 113.0m / Avg Total Assets 1.33b) |
| D: 1.48 (Book Value of Equity 816.7m / Total Liabilities 552.1m) |
| Altman-Z'' = 3.94 = AA |
| DSRI: 0.84 (Receivables 141.2m/142.5m, Revenue 1.87b/1.58b) |
| GMI: 0.41 (GM 6.49% / 15.92%) |
| AQI: 0.71 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 1.19 (Revenue 1.87b / 1.58b) |
| TATA: -0.07 (NI 64.0m - CFO 164.6m) / TA 1.37b) |
| Beneish M = -3.75 (Cap -4..+1) = AAA |
As of October 06, 2026, the stock is trading at EUR 26.56 with a total of 65,710 shares traded. Over the past week, the price has changed by -11.70%, over one month by -16.64%, over three months by -13.37% and over the past year by +118.78%.
Current recommended Stop Loss: 24.70 (which is 7% or 1.3 ATR below the current price).
VERBIO Vereinigte BioEnergie has no consensus analysts rating.
P/E Trailing = 26.72
P/E Forward = 18.8324
P/S = 0.9133
P/B = 2.6355
P/EG = 5.8004
Revenue TTM = 1.87b EUR
EBIT TTM = 113.0m EUR
EBITDA TTM = 169.0m EUR
Long Term Debt = 175.9m EUR (from longTermDebt, two quarters ago)
Short Term Debt = 78.6m EUR (from shortTermDebt, last quarter)
Debt = 253.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 32.1m
Net Debt = 163.1m EUR (calculated: Debt 253.4m - CCE 90.3m)
Enterprise Value = 1.87b EUR (1.71b + Debt 253.4m - CCE 90.3m)
Interest Coverage Ratio = unknown (Ebit TTM 113.0m / Interest Expense TTM 0.0)
EV/FCF = 24.00x (Enterprise Value 1.87b / FCF TTM 78.1m)
FCF Yield = 4.17% (FCF TTM 78.1m / Enterprise Value 1.87b)
FCF Margin = 4.17% (FCF TTM 78.1m / Revenue TTM 1.87b)
Net Margin = 3.42% (Net Income TTM 64.0m / Revenue TTM 1.87b)
Gross Margin = 15.92% ((Revenue TTM 1.87b - Cost of Revenue TTM 1.57b) / Revenue TTM)
Gross Margin QoQ = 19.26% (prev 13.10%)
Tobins Q-Ratio = 1.37 (Enterprise Value 1.87b / Total Assets 1.37b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 253.4m)
Taxrate = 47.74% (58.4m / 122.3m)
NOPAT = 59.0m (EBIT 113.0m * (1 - 47.74%))
Current Ratio = 1.70 (Total Current Assets 608.2m / Total Current Liabilities 358.7m)
Debt / Equity = 0.31 (Debt 253.4m / totalStockholderEquity, last quarter 816.7m)
Debt / EBITDA = 0.97 (Net Debt 163.1m / EBITDA 169.0m)
Debt / FCF = 2.09 (Net Debt 163.1m / FCF TTM 78.1m)
Total Stockholder Equity = 767.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.82% (Net Income 64.0m / Total Assets 1.37b)
RoE = 8.33% (Net Income TTM 64.0m / Total Stockholder Equity 767.8m)
RoCE = 11.97% (EBIT 113.0m / Capital Employed (Equity 767.8m + L.T.Debt 175.9m))
RoIC = 5.91% (NOPAT 59.0m / Invested Capital 998.3m)
WACC = 5.80% (E(1.71b)/V(1.96b) * Re(6.66%) + D(253.4m)/V(1.96b) * Rd(0.0%) * (1-Tc(0.48)))
Discount Rate = 6.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 52.80 | Cagr: 2.52%
[DCF] Terminal Value 75.44% ; FCFF base≈78.1m ; Y1≈78.4m ; Y5≈83.0m
[DCF] Fair Price = 17.63 (EV 1.29b - Net Debt 163.1m = Equity 1.13b / Shares 64.0m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.76 | # QB: 0
Revenue Correlation: -2.60 | Revenue CAGR: -0.23% | SUE: 0.41 | # QB: 0
EPS current Year (2026-06-30): EPS=0.90 | Chg30d=+18.56% | Revisions=+50% | GrowthEPS=+141.5% | GrowthRev=+12.7%
EPS next Year (2027-06-30): EPS=1.71 | Chg30d=-14.67% | Revisions=+0% | GrowthEPS=+71.1% | GrowthRev=+8.1%
[Analyst] Revisions Ratio: +38% (up=4, down=1)